CLINICAL TRIALS PROFILE FOR LIBTAYO
✉ Email this page to a colleague
All Clinical Trials for LIBTAYO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02383212 ↗ | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Completed | Sanofi | Phase 1 | 2015-02-02 | This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies. |
| NCT02383212 ↗ | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Completed | Regeneron Pharmaceuticals | Phase 1 | 2015-02-02 | This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies. |
| NCT02651662 ↗ | Study of Cemiplimab and REGN1979 in Patients With Lymphoma | Active, not recruiting | Regeneron Pharmaceuticals | Phase 1 | 2016-01-11 | This is an open-label, multicenter, dose escalation study of cemiplimab and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients. The primary objective of the study is to assess safety, tolerability and dose-limiting toxicity (DLT) of: - Single-agent cemiplimab in patients with lymphoma (B-NHL and HL) - Combination REGN1979 and cemiplimab in patients with B-NHL The secondary objectives of the study are: - To determine a recommended dose for: - Cemiplimab as a single-agent in patients with lymphoma (B-NHL and HL) - REGN1979 and cemiplimab administered in combination in patients with B-NHL - To characterize the pharmacokinetic (PK) profile of cemiplimab when administered as a single agent and of cemiplimab and REGN1979 when administered in combination - To assess the immunogenicity of cemiplimab when administered alone and the immunogenicity of cemiplimab and REGN1979 when administered in combination - To study the preliminary antitumor activity of cemiplimab as a single agent and of the combination of cemiplimab and REGN1979 in specific indications, as measured by overall response rate, MRD in patients with bone marrow disease at baseline, duration of response, and median progression-free survival and rates at 6 and 12 months |
| NCT02760498 ↗ | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | Regeneron Pharmaceuticals | Phase 2 | 2016-04-07 | For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC. For Group 6, the primary objective is to provide additional efficacy and safety data for cemiplimab monotherapy in patients with advanced CSCC (metastatic [nodal or distant] or locally advanced. Clinical benefit is measured by overall response rate (ORR) according to central review in each group. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIBTAYO
Condition Name
Clinical Trial Locations for LIBTAYO
Trials by Country
Clinical Trial Progress for LIBTAYO
Clinical Trial Phase
Clinical Trial Sponsors for LIBTAYO
Sponsor Name
